Copyright
©The Author(s) 2020.
World J Clin Cases. Jul 6, 2020; 8(13): 2778-2786
Published online Jul 6, 2020. doi: 10.12998/wjcc.v8.i13.2778
Published online Jul 6, 2020. doi: 10.12998/wjcc.v8.i13.2778
Table 1 Demographic and clinical characteristics of the patients at baseline, n (%)
Characteristic | AG | GEM | P value |
Age in yr | 57 (40-72) | 59 (31-67) | |
Sex | 0.787 | ||
Male | 19 (63) | 20 (67) | |
Female | 11 (37) | 10 (33) | |
Performance status | 0.791 | ||
0 | 19 (63.3) | 18 (60) | |
1 | 11 (36.7) | 12 (40) | |
Diabetes | 0.559 | ||
No | 23 (77) | 21 (70) | |
Yes | 7 (23) | 9 (30) | |
Operative procedure | 0.605 | ||
Pancreatoduodenectomy | 15 (50) | 17 (57) | |
Distal pancreatectomy | 15 (50) | 13 (43) | |
Residual tumor status | 0.687 | ||
R0 | 27 (90) | 26 (87) | |
R1 | 3 (10) | 4 (13) | |
Primary tumor status | 0.638 | ||
T1 | 6 (20.0) | 3 (10.0) | |
T2 | 17 (56.7) | 20 (66.7) | |
T3 | 5 (16.6) | 6 (20.0) | |
T4 | 2 (6.7) | 1 (3.3) | |
Regional lymph node status | 0.273 | ||
N0 | 22 (73) | 18 (60) | |
N1 | 8 (27) | 12 (40) | |
Pathological stage | 0.405 | ||
I (IA/IB) | 17 (5/12, 56.7) | 13 (1/12, 43.4) | |
II (IIA/IIB) | 11 (4/7, 36.6) | 16 (5/11, 53.3) | |
III | 2 (6.7) | 1 (3.3) | |
Tumor grade | 0.105 | ||
Well differentiated | 3 (10) | 2 (6.7) | |
Moderately differentiated | 23 (76.7) | 17 (56.7) | |
Poorly differentiated | 4 (13.3) | 11 (36.6) | |
Pre-adjuvant CA19-9, median | 48.2 | 24.6 | 0.795 |
≤ 37 U/mL | 13 (43.4) | 14 (46.7) | |
> 37 U/mL | 17 (56.6) | 16 (53.3) |
Table 2 Adverse events with nab-paclitaxel plus gemcitabine and gemcitabine alone
AG | GEM | P value | P value | |||||
Grade 1/2 (%) | Grade 3/4 (%) | Grade 5 (%) | Grade 1/2 (%) | Grade 3/4 (%) | Grade 5 (%) | Grade ≥ 3 | ||
White blood cell count decreased | 8 (26.7) | 9 (30.0) | 0 | 7 (23.3) | 6 (20.0) | 0 | 0.549 | 0.371 |
Neutropenia | 5 (16.7) | 13 (43.3) | 0 | 4 (13.3) | 9 (30.0) | 0 | 0.435 | 0.284 |
Anemia | 10 (33.3) | 3 (10.0) | 0 | 6 (20.0) | 3 (10.0) | 0 | 0.489 | 1.000 |
Thrombocytopenia | 5 (16.7) | 3 (10.0) | 0 | 2 (6.7) | 2 (6.7) | 0 | 0.394 | 0.639 |
Fatigue | 9 (30.0) | 4 (13.3) | 0 | 6 (20.0) | 2 (6.7) | 0 | 0.382 | 0.385 |
Vomiting | 10 (33.3) | 3 (10.0) | 1 (3.3) | 8 (26.7) | 0 | 1 (3.3) | 0.168 | 0.148 |
Diarrhea | 8 (26.7) | 1 (3.3) | 0 | 6 (20.0) | 0 | 0 | 0.392 | 1.000 |
Fever | 8 (26.7) | 2 (6.7) | 0 | 5 (16.7) | 1 (3.3) | 0 | 0.496 | 0.550 |
Febrile neutropenia | 2 (6.7) | 4 (13.3) | 1 (3.3) | 3 (10.0) | 1 (3.3) | 0 | 0.296 | 0.073 |
Infection | 2 (6.7) | 1 (3.3) | 1 (3.3) | 1 (3.3) | 1 (3.3) | 0 | 0.615 | 0.550 |
Sensory neuropathy | 14 (46.7) | 15 (50.0) | 1 (3.3) | 7 (23.3) | 0 | 0 | < 0.001 | < 0.001 |
- Citation: Yin ZZ, Zhao ZM, Tang WB, Jiang N, Zhang KD, Song YY, Wang Y, Li CG, Gao YX, Liu R. Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China. World J Clin Cases 2020; 8(13): 2778-2786
- URL: https://www.wjgnet.com/2307-8960/full/v8/i13/2778.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i13.2778